Skip to content

Safety and Efficacy of Using CBUS™ System for Ultrasound Breast Imaging Designed for Breast Tumor Diagnosis

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00355745
Enrollment
50
Registered
2006-07-25
Start date
2006-07-31
Completion date
2009-07-31
Last updated
2011-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast, tumor, ultrasound, biopsy, Breast mammographic or ultrasound findings

Brief summary

In the United States, breast cancer is the most common cancer occurring in women (excluding cancers of the skin) and the second most common cause of death from cancer in women (after lung cancer). Approximately 182,800 new cases per year occur in the United States, causing 40,800 death cases per year. Breast cancer is the leading cause of death in women aged 44-50 years. The 5-year survival rate is 60% overall but is greater than 80% for early disease. If diagnosed at an early stage, breast cancer has an encouraging cure rate: up to 97% of women diagnosed with localized breast cancer will survive five years after their diagnosis. Even if the cancer is found at a more advanced stage, new therapies have enabled many people with breast cancer to experience the same quality of life as before their diagnosis. Breast ultrasound (US) is an extremely useful modality in the diagnosis of breast disease in the symptomatic clinic. It is routinely used as an adjunct to x-ray mammography and clinical examination and, with younger patients it may be the sole imaging modality. It has well-established value in differentiating between malignant and benign solid lesions in some cases, however, it cannot replace fine needle aspiration and core biopsy. Conventional breast US scanning is highly operator- dependent, requiring skillful probe manipulation and the mental ability to envisage 3-D tissue structure. Acquiring 3-D US data sets may be advantageous, making it easier to see and interpret 3-D structures, boundaries and interactions. CBUS™, Circular Breast Ultrasound Scanner is indicated to improve significantly breast images obtained by ultrasound systems. The CBUS™ system automatically acquires a complete breast image and constructs a high quality 3D image of the scanned breast. These images provide diagnostic information of the complete volume of breast tissue including blood flow in a single ultrasonic 3D image. In this clinical study, the CBUS™ Circular Breast Ultrasound Scanner will be used to automatically image the complete breast and provides a high quality 3D image of the scanned breast.

Interventions

DEVICEUltrasound breast scanning

breast scanning

Sponsors

Helix Medical Systems
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Female age between 21-70 years. * Subject has mammography or ultrasound findings * Subject is scheduled for biopsy. * Subject is scheduled for ultrasound breast scan. * Subject understands the study procedure. * Subject is willing to sign the inform consent and comply with the study requirements.

Exclusion criteria

* Age \< 21 years or \> 70 years. * Subject undergo previous breast surgery * Known blood coagulation disorders. * Known cardiac disorders. * Breast infection / breast abscess / breast pains. * Ipsilateral breast scar in same quadrant as current lesion * Recent breast trauma. * Pregnant or lactating woman * Subject has bleeding disorder. * Subject is suffering extreme general weakness. * Subject objects to the study protocol. * Physician objection. * Known cognitive or psychiatric disorder * Participation in any other clinical trial

Design outcomes

Primary

MeasureTime frame
Occurrences of adverse eventsimmediately

Secondary

MeasureTime frame
Quality of ultrasound imagingwithin 1 day

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026